Arcutis Biotherapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Arcutis Biotherapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2019 to Q3 2024.
  • Arcutis Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $10.2M, a 2.42% increase year-over-year.
  • Arcutis Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $41.6M, a 5.67% increase year-over-year.
  • Arcutis Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $38.8M, a 18.8% increase from 2022.
  • Arcutis Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $32.7M, a 36.8% increase from 2021.
  • Arcutis Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $23.9M, a 201% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $41.6M $10.2M +$242K +2.42% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $41.3M $12.5M +$1.95M +18.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $39.4M $10M +$551K +5.81% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $38.8M $8.76M -$507K -5.47% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $39.3M $10M +$1.21M +13.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $38.1M $10.6M +$2.48M +30.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $35.6M $9.48M +$2.95M +45.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $32.7M $9.26M +$3.58M +62.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $29.1M $8.79M +$3.43M +63.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 $25.7M $8.1M +$3.76M +86.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $21.9M $6.53M -$1.97M -23.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $23.9M $5.69M +$3.04M +115% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $20.8M $5.36M +$3.1M +137% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $17.7M $4.34M +$2.29M +112% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $15.5M $8.5M +$7.51M +759% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $7.94M $2.64M +$2.17M +462% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $5.77M $2.26M +$2.12M +1527% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $3.65M $2.05M +$1.91M +1374% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $1.74M $990K +$914K +1203% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $824K $470K Oct 1, 2019 Dec 31, 2019 10-K 2022-02-22
Q3 2019 $139K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $139K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $76K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.